Australia markets open in 5 hours 3 minutes

DuPont's (DD) Q1 Earnings Beat Estimates, Sales Miss

Zacks Equity Research

DuPont de Nemours, Inc. DD provides technology-based materials, ingredients and solutions. It serves several markets including electronics, transportation and construction.

Earnings

DuPont’s adjusted earnings were 84 cents per share for the first quarter. The figure beat the Zacks Consensus Estimate of 83 cents.

Revenues

DuPont posted revenues of $5,221 million. It missed the Zacks Consensus Estimate of $5,231.4 million.  
 

DuPont de Nemours, Inc. Price and EPS Surprise

 

DuPont de Nemours, Inc. Price and EPS Surprise

DuPont de Nemours, Inc. price-eps-surprise | DuPont de Nemours, Inc. Quote

 

Estimate Trend

Investors should note that the earnings estimate for DuPont for the first quarter have been going up over the past month.

Key Stats/Developments to Note

DuPont now sees $180 million of savings in 2020 from its earlier announced incremental cost actions. It has also implemented actions to mitigate the impact of the coronavirus pandemic. These include actions to deliver more than $500 million of working capital improvement and reduction of capital expenditures by roughly $500 million versus the prior year.

Zacks Rank

DuPont currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Market Reaction

DuPont’s shares were up 2.6% in pre-market trading. It would be interesting to see how the market reacts to the results during the trading session today.

Check back later for our full write up on DuPont’s earnings report!

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research